Please login to the form below
Novartis' patupilone fails phase III trial
Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer
Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.
The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).
The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.
Featured jobs
-
Business Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Medical Writer
-
Salary TBC
-
Account Manager / Account Director
-
Competative
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
- NHS regional footprints
- Not another weight-loss ad
- GENERATION Z IS FEARFUL FOR THE FUTURE OF UK HEALTH SERVICES, SAYS NEW REPORT
- UK businesses leaning towards second Brexit vote
- Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
- Immunomedics craters after FDA rejects breast cancer ADC
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
